Journal of Pancreatic Cancer
Overview
Journal of Pancreatic Cancer is a scientific journal, published since 2017 in English. The journal's country of origin is United States.
Details
Details
Recent Articles
21.
Tan M, de Muckadell O, Joergensen M
J Pancreat Cancer
. 2020 Aug;
6(1):73-84.
PMID: 32783019
High-grade pancreatic intraepithelial neoplasia (PanIN) are aggressive premalignant lesions, associated with risk of progression to pancreatic ductal adenocarcinoma (PDAC). A depiction of co-dysregulated gene activity in high-grade familial pancreatic cancer...
22.
Shah M, NeMoyer R, Greco S, Chen C, Moore D, Grandhi M, et al.
J Pancreat Cancer
. 2020 Aug;
6(1):64-72.
PMID: 32766509
According to the American Joint Committee on Cancer (AJCC) 7th edition, T1 staging of pancreatic adenocarcinoma (PC) is defined as tumor limited to the pancreas, ≤2 cm. The AJCC 8th...
23.
Savitch S, Bauer T, Alvarez N, Johnson A, Yeo T, Lavu H, et al.
J Pancreat Cancer
. 2020 Jul;
6(1):55-63.
PMID: 32642631
Our institution's hepatopancreaticobiliary surgery service (HPBS) has demonstrated low rates of venous thromboembolism (VTE). We sought to determine whether the HPBS's regimented multimodal VTE prophylaxis pathway, which includes the use...
24.
Weinberg B, Wang H, Witkiewicz A, Marshall J, He A, Vail P, et al.
J Pancreat Cancer
. 2020 Jul;
6(1):45-54.
PMID: 32642630
Metastatic pancreatic adenocarcinoma (mPC) has a poor prognosis. CDK4/6 is often deregulated in mPC due to loss, resulting in the loss of p16INK4a that inhibits CDK4/6. CDK4/6 inhibitor monotherapy is...
25.
Aizikovich A
J Pancreat Cancer
. 2020 Jul;
6(1):40-44.
PMID: 32642629
New tetrahydrocannabinolic acid (THCA) derivatives ALAM027 and ALAM108 were proposed for the treatment of the pancreatic cancer disease. The effect of new cannabinoids ALAM027 and ALAM108 was tested against PANC-1...
26.
Zheng R, Wang O, Bradley E, Lavu H, Winter J, Rosato E, et al.
J Pancreat Cancer
. 2020 May;
6(1):32-39.
PMID: 32462109
The neutrophil-to-lymphocyte ratio (NLR) is a marker of inflammation that has been investigated as a prognostic factor in many diseases. We hypothesized that NLR would be lower in patients undergoing...
27.
OHara M, Messersmith W, Kindler H, Zhang W, Pitou C, Szpurka A, et al.
J Pancreat Cancer
. 2020 Mar;
6(1):21-31.
PMID: 32219196
This was an open-label phase 1a study assessing the maximum tolerated dose (MTD), safety, and tolerability of CXCR4 peptide antagonist, LY2510924, administered in combination with durvalumab in patients with advanced...
28.
Soreide K, Roalso M, Aunan J
J Pancreat Cancer
. 2020 Feb;
6(1):12-20.
PMID: 32064449
Pancreatic cancer is one of the most lethal of solid tumors and is associated with aggressive cancer biology. The purpose is to review the role of trypsin and effect on...
29.
Honig S, Lundgren M, Kowalski T, Lavu H, Yeo C
J Pancreat Cancer
. 2020 Feb;
6(1):5-11.
PMID: 32064448
Approximately 4% of patients develop a second upper gastrointestinal cancer after esophagectomy, and nearly 60,000 people are diagnosed with pancreatic cancer in the United States each year. The need for...
30.
Stuart C, Lundgren M, Lavu H, Yeo C
J Pancreat Cancer
. 2020 Feb;
6(1):1-4.
PMID: 32043065
Intraductal papillary mucinous neoplasms (IPMNs) are cystic lesions of the pancreas with malignant potential. The Sendai and Fukuoka criteria offer guidelines for surgical management of an IPMN. A 69-year-old patient...